苯磺酸氨氯地平联合缬沙坦治疗CKD1期合并高血压的临床疗效观察

Clinical Efficacy of Amlodipine Besylate Combined with Valsartan in the Treatment of CKD1 with Hypertension

摘要: 目的：观察苯磺酸氨氯地平联合缬沙坦治疗慢性肾脏病(CKD) 1期合并高血压的临床效果。方法：选取我院于2018年10月~2019年5月收治的95例CKD1期合并高血压患者为研究对象。依据治疗方法分组，分成对照组(47例)和观察组(48例)。分别给予两组常规苯磺酸氨氯地平治疗、苯磺酸氨氯地平联合缬沙坦治疗。结果：观察组治疗后舒张压、收缩压均低于对照组，差异存在统计学意义(P < 0.05)。观察组治疗后24小时尿蛋白低于对照组，差异存在统计学意义(P < 0.05)。结论：苯磺酸氨氯地平联合缬沙坦用于CKD1期合并高血压的治疗，可有效改善患者的血压及尿蛋白，延缓肾脏病变。

Abstract: Objective: To observe the clinical effect of amlodipine besylate combined with valsartan in the treatment of chronic kidney disease with stage 1 (CKD) complicated with hypertension. Methods: A total of 95 patients with chronic kidney disease complicated with hypertension who were admitted to our hospital from October 2018 to May 2019 were enrolled. According to the treatment, they were divided into control group (47 cases) and observation group (48 cases). Two groups were treated with conventional amlodipine besylate and amlodipine besylate combined with valsartan. Results: The diastolic blood pressure and systolic blood pressure of the observation group were lower than those of the control group, and the difference was statistically significant (P < 0.05). Urinary protein was lower in the observation group than in the control group 24 hours after treatment, and the difference was statistically significant (P < 0.05). Conclusion: Amlodipine combined with valsartan for the treatment of chronic kidney disease with stage 1 hypertension can effectively improve blood pressure and urine protein and delay renal disease.